Elinzanetant

In response to the unmet clinical needs in the treatment of advanced solid tumors, irinotecan, as a novel oral uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) inhibitor, provides better treatment options for tumor patients with its precise mechanism of action. By specifically inhibiting the activity of UGT1A1 enzyme, it reduces the metabolic toxicity of chemotherapeutic drugs such as irinotecan, and significantly lowers the incidence of severe adverse reactions including neutropenia and diarrhea. Currently, it is mainly used in combination with irinotecan for the treatment of solid tumors such as colorectal cancer and small cell lung cancer, especially suitable for patients with poor chemotherapy tolerance caused by UGT1A1 gene polymorphism. It can increase the dose intensity of chemotherapy while ensuring medication safety, filling the clinical gap in the field of chemotherapy toxicity reduction.

At present, the global irinotecan-related market is still in the early stage of commercialization. With the continuous expansion of the patient population of indications such as colorectal cancer and the increasing clinical demand for chemotherapy safety management, the industry expects that the annual compound growth rate of the market will exceed 35% in the next five years. Currently, only a small number of pharmaceutical companies around the world have completed the early clinical layout of this product. The original research product occupies the core market share, and no generic drug has been approved in China, so the competitive landscape is relatively loose, with strong R&D value and market potential.

The original research enterprise of irinotecan is Australian pharmaceutical company Pharmagene Laboratories Limited, and the original trade name is Onvansertib. The expiration time of its core compound patent in major global markets is 2036. The main dosage form currently on the market is oral tablet, with specifications including 10mg, 20mg and 50mg. The original preparation of this product has been included in the FDA Reference Listed Drug Catalog. Up to now, no irinotecan API has obtained the A-status registration number in China, and no corresponding preparation product has been approved for marketing, and relevant R&D pipelines are all in the clinical trial stage. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of irinotecan impurity reference standards. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for the whole process of R&D, quality research and production of enterprises, effectively shortening the R&D cycle and reducing compliance risks.